← All trials
NCT05252364
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 14, 2021
- Primary completion
- Dec 31, 2024
- Completion date
- Apr 29, 2025
- First posted
- Feb 23, 2022
- Last posted
- Dec 21, 2022
- Enrollment
- 65
- Arms / groups
- 11 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hinova Pharmaceuticals Aus Pty LtdLead sponsor
- Hinova Pharmaceuticals, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.